Cabozantinib (Cabometyx) for the treatment of advanced hepatocellular carcinoma (liver cancer)


Cabozantinib (trade name: Cabometyx) has been approved in Germany since November 2018 for the treatment of advanced hepatocellular carcinoma in adults who have already had treatment with the drug sorafenib.

Hepatocellular carcinoma is caused by malignant changes in the cells of the liver. It is usually not very noticeable at first. Symptoms such as nausea or loss of appetite don’t occur until it reaches an advanced stage. Large tumors cause tenderness on the right side of the upper abdomen. The tummy may swell as a result of fluids building up there (ascites). This type of cancer is usually caused by liver cirrhosis (liver damage due to scarring), which leads to a decline in the function of the liver. Hepatocellular carcinoma is difficult to treat. By the time it is detected, it may have already grown so much that surgery is no longer a treatment option.

The goal of treatment with cabozantinib is to block various proteins (enzymes) in order to reduce tumor growth.


Cabozantinib is available in tablet form, in doses of 20, 40, and 60 mg. The recommended dose is 60 mg a day. The dosage depends on how well the patient tolerates the drug and the side effects, and can be adjusted individually by a doctor. Treatment is stopped if the disease gets worse or if very severe side effects arise.

Other treatments

Best supportive care (BSC) is an option for adults with advanced hepatocellular carcinoma. This treatment should be tailored to the patient’s individual needs, relieve symptoms such as pain, and improve their quality of life.


In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of cabozantinib compared with BSC for the treatment of hepatocellular carcinoma in people who have already had treatment with sorafenib.

The manufacturer provided one study for the purpose of this comparison. The study involved one group of 512 patients who had treatment with cabozantinib and another group of 261 participants who received a dummy drug (a placebo). Both groups also had BSC. The study only included people who could no longer have surgery to cure the cancer, such as a liver transplant or removal of the tumor, and whose liver function had only slightly worsened. Despite the advanced stage of the disease, patients were otherwise in good general health. The study produced the following results for these patients:

What are the advantages of cabozantinib?

Life expectancy: The study suggests that cabozantinib has an advantage here: In this group, participants had passed away within an average of about 10 months (median value), compared to 8 months in the placebo group.

What are the disadvantages of cabozantinib?

  • Serious side effects: The study suggests that there is a disadvantage here. Serious side effects occurred in 84 out of 100 people who took cabozantinib, but only in about 51 out of 100 people who took a placebo.
  • These serious side effects included:
    • Disorders of the nervous system
    • Loss of appetite
    • Diarrhea
    • Exhaustion
    • High blood pressure
    • Hand-foot syndrome
  • Treatment stopped due to side effects: The study suggests that cabozantinib has a disadvantage here. 35 out of 100 participants in this group stopped their treatment mainly due to severe side effects, compared to only about 18 out of 100 people in the placebo group.
  • Inflammation of the mucous membranes: The study suggests that cabozantinib has a disadvantage in terms of this side effect, too.

No differences

There was no noticeable difference between cabozantinib and the placebo in terms of general health.

What remains unanswered?

Health-related quality of life: The manufacturer didn't provide any data about quality of life.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of cabozantinib (Cabometyx).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-85. March 13, 2019. (IQWiG reports; Volume 739).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on April 11, 2019
Next planned update: 2022


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.